Results 11 to 20 of about 12,689 (257)

Cost-effectiveness analysis of patent foramen ovale closure versus medical therapy alone after cryptogenic stroke.

PLoS ONE, 2022
BackgroundClosure of a patent foramen ovale reduces the risk of recurrent stroke compared with medical therapy alone in young patients with cryptogenic strokes revealed by randomized control trials.
Yoko Shijoh, Shota Saito, Zhehao Dai, Sachiko Ohde   +3 more
doaj   +3 more sources

Cost, incremental cost, effectiveness, incremental effectiveness, cost-effectiveness ratio, and incremental cost-effectiveness ratio of Ebola screening-action algorithms based on baseline value.

, 2023
Cost, incremental cost, effectiveness, incremental effectiveness, cost-effectiveness ratio, and incremental cost-effectiveness ratio of Ebola screening-action algorithms based on baseline value.
Charles T. Kayembe (14271437), Olivier M. Tshiani (14271431), Jean-Jacques Muyembe-Tamfum (122740), Daniel Mukadi-Bamuleka (17053944), Dieudonné N. Mumba (14271440), Désiré D. Tshala-Katumbay (14271443), Steve Ahuka-Mundeke (284741), Bart Karl M. Jacobs (17181393), Antoine Oloma Tshomba (14271425), Faustin M. Chenge (17181390), Sabue Mulangu (364641), Anja De Weggheleire (144112), Placide Mbala-Kingebeni (9331430)   +12 more
core   +1 more source

Cost-utility analysis of total knee arthroplasty alone and in comparison with post-surgical rehabilitation and conservative treatment in the Republic of Kazakhstan

Cost Effectiveness and Resource Allocation, 2022
Background Despite ample international knowledge on cost-effectiveness of total knee arthroplasty (TKA), it has never been a subject of investigation in Kazakhstan or other post-Soviet economies.
Dinara Serikova-Esengeldina, Natalya Glushkova, Gulzada Abdushukurova, Akmaral Mussakhanova, Ainur Mukhamejanova, Zaituna Khismetova, Dmitry Bokov, Alexandr Ivankov, Maiya Goremykina, Yuliya Semenova   +9 more
doaj   +1 more source

Median-based incremental cost-effectiveness ratios with censored data [PDF]

Journal of Biopharmaceutical Statistics, 2015
Cost-effectiveness is an essential part of treatment evaluation, in addition to effectiveness. In the cost-effectiveness analysis, a measure called the incremental cost-effectiveness ratio (ICER) is widely utilized, and the mean cost and the mean (quality-adjusted) life years have served as norms to summarize cost and effectiveness for a study ...
Bang, Heejung, Zhao, Hongwei
openaire   +4 more sources

Incremental cost-effectiveness ratio (ICER).

, 2021
Incremental cost-effectiveness ratio (ICER).
Christian Auer (4094623), Dachi Arikpo (10661232), Ekperonne Esu (11442197), Angela E. Oyo-Ita (11442188), Patrick Hanlon (11442191), Ogonna Nwankwo (11442194), Martin Meremikwu (558006), Xavier Bosch-Capblanch (176679)   +7 more
core   +1 more source

Cost-effectiveness plane and Incremental Cost-Effectiveness Ratio of COTiD-UK vs TAU.

, 2022
Cost-effectiveness plane showing that the Incremental Cost-Effectiveness Ratio (ICER) of COTiD-UK vs TAU is always above the lower (£20,000 per QALY) and upper (£30,000 per QALY) willingness to pay threshold for a QALY.
Elena Pizzo (5980439), Jennifer Wenborn (4824852), Stephen Morris (324510), Jacqueline Mundy (9529284), Rumana Omar (447230), Martin Orrell (2616487), Jane Burgess (8177532), Michael King (42679)   +7 more
core   +1 more source

Nonparametric inference for time‐dependent incremental cost‐effectiveness ratios [PDF]

Statistics in Medicine, 2015
As the costs of medical care increase, more studies are evaluating cost in addition to effectiveness of treatments. Cost‐effectiveness analyses in randomized clinical trials have typically been conducted only at the end of follow‐up. However, cost‐effectiveness may change over time.
Laura M, Yee, Kwun Chuen, Gary Chan
openaire   +2 more sources

Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation [PDF]

, 2006
Background: The cost-effectiveness acceptability curve (CEAC) is a method for summarizing the uncertainty in estimates of cost-effectiveness. The CEAC, derived from the joint distribution of costs and effects, illustrates the (Bayesian) probability ...
Deborah A Marshall, Levy, Adrian R, Nichol, G., Fenwick Elisabeth, Adrian R Levy, Fenwick, E., Graham Nichol, Elisabeth Fenwick, Marshall, Deborah A, Nichol, Graham, Marshall, D.A., Levy, A.R., Levy Adrian R, Marshall Deborah A, Nichol Graham, Fenwick, Elisabeth   +15 more
core   +1 more source

Cost-effectiveness analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Olanzapine has been shown to have an additive effect on the three-drug antiemetic therapy consisting of aprepitant, palonosetron, and dexamethasone, in a highly emetogenic cisplatin-containing chemotherapy.
Yu Kondo, Tomoya Tachi, Takayoshi Sakakibara, Jun Kato, Takahito Mizuno, Yoshio Miyake, Hitomi Teramachi   +6 more
doaj   +1 more source

Results of Monte Carlo simulations depicted in incremental-cost-effectiveness-ratio (ICER) planes and cost-effectiveness-acceptability curves (CEAC).

, 2020
Results of Monte Carlo simulations depicted in incremental-cost-effectiveness-ratio (ICER) planes and cost-effectiveness-acceptability curves (CEAC).
Benjamin Birkner (8212203), Jürgen Rech (3741517), Tom Stargardt (5064095)   +2 more
core   +1 more source